ArticleCancer research2006
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
Article in Cancer research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01258868 (Epigenetically-Modified Autologous Tumor Cell Vaccines With ISCOMATRIX), which is not on this map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epigenetically-Modified Autologous Tumor Cell Vaccines With ISCOMATRIX(TM) Adjuvant and Oral Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.
- The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.Annals of hematology · 2025Pooled it
- A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.Blood advances · 2022Trial
- A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.Blood advances · 2022Trial
- Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.British journal of haematology · 2012Trial
- Azacytidine restores T cell function in AML by modulating DNA methylation.bioRxiv : the preprint server for biology · 2026Article
- Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies.Transplantation and cellular therapy · 2026Article
- Novel H-2DJournal for immunotherapy of cancer · 2024Article
- Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy.Molecular therapy. Oncology · 2024Article
- Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential.Cancers · 2023Review
- Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.Molecular cancer · 2022Review
- Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.Journal for immunotherapy of cancer · 2022Article
- Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.Molecular cancer · 2021Review
- Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.Molecular cancer therapeutics · 2021Article
- Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies.Translational lung cancer research · 2021Article
- Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.Frontiers in immunology · 2021Review
- Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.Cancer immunology, immunotherapy : CII · 2020Review
- Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.Journal of clinical medicine · 2020Review
- CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens.Frontiers in immunology · 2020Review
- Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia.International journal of medical sciences · 2020Article
- Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.Frontiers in immunology · 2020Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Recent studies suggest that immunotherapy targeting specific tumor-associated antigens (TAAs) may be beneficial in cancer patients. However, most of these TAAs are tumor type specific and heterogeneous among patients, thus limiting their applications. Here, we describe the de novo induction of a cancer/testis antigen (CTA) for immunotherapy of tumors of various histologies. The murine CTA P1A, normally expressed only in a few tumor lines, could be induced de novo in all P1A-negative cancer lines of eight histologic origins in vitro and in various murine xenografts by systemic administration of 5-aza-2'-deoxycytidine. The induction of P1A expression correlated strongly with demethylation of the CpG island in the promoter region of this gene. The induced antigen was processed and presented properly for recognition by H-2L(d)-restricted P1A-specific CTLs. The combination of a demethylating agent and adoptive transfer of P1A-specific CTL effectively treated lung metastases in syngeneic mice challenged with P1A-negative 4T1 mammary carcinoma cells. These data show a novel strategy of combined chemoimmunotherapy of cancer targeting a CTA induced de novo in a broad range of tumor histologies, and support further evaluation of chromatin-remodeling agents for human cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.